Six accepted abstracts at ASGCT 2025 detail the therapeutic potential of HSC gene therapy to address severe multi-system diseases TOKYO, LONDON and BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Orchard ...

Treatment with Lenmeldy was well-tolerated, with no treatment-related serious adverse events. Most adverse events were associated with busulfan conditioning or background disease. The most common ...

Treatment with Lenmeldy was well-tolerated, with no treatment-related serious adverse events. Most adverse events were associated with busulfan conditioning or background disease. The most common ...

News GlobeNewswire Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025 ...

DURHAM, N.C., May 01, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo ...

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced presentations at the ...

Session ID: 2025-04-21:c3e051095e72ac9cd4316e92 Player Element ID: Vc907bc3e_bda3_4228_9812_d0ae0d2e1297_6363302043112 ...

There is no better time than now to study human genetics. The completion of the Human Genome Project, alongside huge strides forward in technology, means that scientists can now gain a far better ...